Subgroup | n | Anti–PD-1/ PD-L1 monotherapy, n (%) | Atezolizumab, n (%) | Nivolumab, n (%) | Pembrolizumab, n (%) | Anti–PD-1/ PD-L1 therapy + platinum-based CT, n (%) | Pembrolizumab + platinum-based CT, n (%) | Anti–PD-1/ PD-L1 therapy + any therapy other than platinum-based CT, n (%) | Nivolumab + ipilimumab, n (%) |
---|---|---|---|---|---|---|---|---|---|
Age group | |||||||||
<65 years | 846 | 379 (44.8) | 17 (4.5) | 100 (26.4) | 262 (69.1) | 447 (52.8) | 429 (96.0) | 20 (2.4) | 9 (45.0) |
65–74 years | 759 | 361 (47.6) | 18 (5.0) | 87 (24.1) | 256 (70.9) | 357 (47.0) | 344 (96.4) | 41 (5.4) | 22 (53.7) |
≥75 years | 570 | 363 (63.7) | 23 (6.3) | 84 (23.1) | 256 (70.5) | 185 (32.5) | 177 (95.7) | 22 (3.9) | 16 (72.7) |
Sex | |||||||||
Male | 1169 | 581 (49.7) | 36 (6.2) | 137 (23.6) | 408 (70.2) | 548 (46.9) | 526 (96.0) | 40 (3.4) | 23 (57.5) |
Female | 1006 | 522 (51.9) | 22 (4.2) | 134 (25.7) | 366 (70.1) | 441 (43.8) | 424 (96.1) | 43 (4.3) | 24 (55.8) |
Histology | |||||||||
Nonsquamous | 1447 | 691 (47.8) | 31 (4.5) | 154 (22.3) | 506 (73.2) | 705 (48.7) | 686 (97.3) | 51 (3.5) | 25 (49.0) |
Squamous | 457 | 267 (58.4) | 19 (7.1) | 84 (31.5) | 164 (61.4) | 168 (36.8) | 164 (97.6) | 22 (4.8) | 18 (81.8) |
Number of metastatic sites | |||||||||
0 | 23 | 12 (52.2) | 1 (8.3) | 5 (41.7) | 6 (50.0) | 9 (39.1) | 9 (100.0) | 2 (8.7) | 2 (100.0) |
1 | 1404 | 734 (52.3) | 42 (5.7) | 189 (25.7) | 503 (68.5) | 616 (43.9) | 592 (96.1) | 54 (3.8) | 33 (61.1) |
2 | 504 | 243 (48.2) | 9 (3.7) | 46 (18.9) | 188 (77.4) | 238 (47.2) | 230 (96.6) | 23 (4.6) | 11 (47.8) |
≥3 | 173 | 73 (42.2) | 1 (1.4) | 19 (26.0) | 53 (72.6) | 97 (56.1) | 91 (93.8) | 3 (1.7) | 0 |
NSCLC stage at index date | |||||||||
3 | 78 | 42 (53.8) | 4 (9.5) | 12 (28.6) | 26 (61.9) | 33 (42.3) | 32 (97.0) | 3 (3.8) | 2 (66.7) |
4 | 2097 | 1061 (50.6) | 54 (5.1) | 259 (24.4) | 748 (70.5) | 956 (45.6) | 918 (96.0) | 80 (3.8) | 45 (56.3) |
Brain metastases | |||||||||
Yes | 499 | 261 (52.3) | 9 (3.4) | 50 (19.2) | 202 (77.4) | 221 (44.3) | 210 (95.0) | 17 (3.4) | 8 (47.1) |
No | 1676 | 842 (50.2) | 49 (5.8) | 221 (26.2) | 572 (67.9) | 768 (45.8) | 740 (96.4) | 66 (3.9) | 39 (59.1) |
ECOG PS | |||||||||
0 or 1 | 1408 | 653 (46.4) | 26 (4.0) | 152 (23.3) | 475 (72.7) | 698 (49.6) | 670 (96.0) | 57 (4.0) | 35 (61.4) |
≥2 | 430 | 242 (56.3) | 8 (3.3) | 61 (25.2) | 173 (71.5) | 171 (39.8) | 163 (95.3) | 17 (4.0) | 7 (41.2) |
Smoking status | |||||||||
Current or former | 1912 | 946 (49.5) | 45 (4.8) | 226 (23.9) | 675 (71.4) | 897 (46.9) | 860 (95.9) | 69 (3.6) | 41 (59.4) |
Never | 263 | 157 (59.7) | 13 (8.3) | 45 (28.7) | 99 (63.1) | 92 (35.0) | 90 (97.8) | 14 (5.3) | 6 (42.9) |
Patient immunocompromiseda, b | |||||||||
Yes | 240 | 126 (52.5) | 9 (7.1) | 37 (29.4) | 80 (63.5) | 95 (39.6) | 86 (90.5) | 19 (7.9) | 11 (57.9) |
History of autoimmune disease | |||||||||
Yes | 33 | 11 (33.3) | 1 (9.1) | 4 (36.4) | 6 (54.5) | 15 (45.5) | 14 (93.3) | 7 (21.2) | 5 (71.4) |
No | 2142 | 1092 (51.0) | 57 (5.2) | 267 (24.5) | 768 (70.3) | 974 (45.5) | 936 (96.1) | 76 (3.5) | 42 (55.3) |
Patients positive for RET, BRAF, or MET mutations | |||||||||
Yes | 179 | 94 (52.5) | 1 (1.1) | 20 (21.3) | 73 (77.7) | 77 (43.0) | 75 (97.4) | 8 (4.5) | 4 (50.0) |
PD-1/PD-L1 expressionc | |||||||||
1–49% | 62 | 27 (43.5) | 5 (18.5) | 10 (37.0) | 12 (44.4) | 35 (56.5) | 35 (100.0) | 0 | 0 |
≥50% | 115 | 84 (73.0) | 1 (1.2) | 6 (7.1) | 77 (91.7) | 26 (22.6) | 23 (88.5) | 5 (4.3) | 0 |